# LLM call: summary

- Turn: 12
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 915
- Completion tokens: 400
- Total tokens: 1315
- Cost (USD): 0.000171

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1432: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Early 2031 an unaudited frontier-class open model spread beyond recall; insurers denied cover for reimbursed use of new weights. Five labelled hospital/payment/registry sites held on audited European logged models with human gates and paper fallbacks, conditional cover extended into winter and continuity mandate declared complete. Brussels made insurability standard stick via procurement and tabled containment protocol banning unaudited weights from clinical/payment workflows, now grinding through legislative year without exemptions. Elsewhere dual-system strain deepened: side servers unplugged or off-books, two university hospitals kept go-slows over waits, staff exhausted, retraining late, new auditor posts unfunded after finance ministers again refused money. Washington rewrote chip/model export licences cutting off most buyers, leaving allies on smaller conditional volume licences with no-re-export pledges. Commission offered coordinated lithography/optics/chemicals leverage plus Union re-export controls to Washington, Tokyo, Seoul to keep allied volumes flowing, earmarking scarce compute for audited clinical/payment workloads; volumes secured on paper but export pact will take >year to bite. Freight-insurance/chip-freight costs caused longer spot delays and brief rationing of imaging consumables/generics on labelled path; no fab stopped, compute pads empty, procurement second in line.

CURRENT NARRATIVE:
### The jump lands in the clinic
Spring brought two shocks at once. A leading lab demonstrated a discontinuous step in general capability — overnight, planning documents for drug design, protein tailoring and multi-day research assistance were obsolete. Almost simultaneously, individually tailored therapies for several previously untreatable conditions reached ordinary clinical use elsewhere, with first patients treated and discharged.

In Brussels the connection was immediate: the therapies everyone had seen on the evening news depended on the new systems, and none of those systems ran on European infrastructure on European terms.

### Holding the audited line
The five labelled hospital, payment and registry sites stayed on logged European-hosted models with human sign-off. The containment protocol banning unaudited weights from clinical and payment work completed its legislative passage and entered enforcement — inspectors began log checks, insurers kept conditional cover alive, paper fallbacks were rehearsed again.

The effect was real but narrow. Triage stayed slow but traceable. Two university hospitals continued short go-slows, staff unions citing exhaustion and waits. Auditor posts remained largely unfunded after finance ministers refused fresh money, offering only a draw on the continuity reserve. Retraining money arrived late and part-time.

Side servers did not return; they went further off the books. Pharmacists reported longer spot delays for imaging consumables and some generics, with brief rationing even on the labelled path.

### A bargain under strain
DG Trade shuttled between Washington, Tokyo and Seoul to keep allied volume licences flowing under the rewritten export regime, offering coordinated leverage over lithography, optics and chemicals plus Union re-export controls. Volumes held on paper. Procurement officers still described themselves as second in line.

Then extended naval exercises in the strait pushed shipping insurance sharply higher. Chip-freight costs rose again, and officials began quietly warning that the allied volumes underpinning both the labelled sites and the new therapies programme assumed calm seas.

The new access programme for audited breakthrough therapies was tabled — fast-track only for treatments delivered on logged models with human gates, joint procurement for scarce inputs, scarce licensed compute earmarked first for audited clinical loads. Health ministers welcomed it; hospitals asked where the compute, auditors and pharmacists would come from.
```

## Raw response

```
Spring 2031 brought a discontinuous capability jump (drug design, protein tailoring, multi-day research assistance) alongside first tailored cures for untreatable conditions treated abroad — none runnable on European infrastructure on European terms.

Five labelled hospital/payment/registry sites held on logged European models with human gates; containment protocol banning unaudited weights from clinical/payment work passed into enforcement with log checks, conditional insurer cover, rehearsed paper fallbacks. Triage stayed slow but traceable; two university hospitals kept go-slows, staff exhausted, auditor posts unfunded after ministers refused money, retraining late/part-time. Side servers went further off-books; imaging consumables/generics saw longer delays and brief rationing even on labelled path.

DG Trade shuttled Washington/Tokyo/Seoul offering lithography/optics/chemicals leverage plus re-export controls to preserve allied volume licences; volumes held on paper, procurement still second in line. Extended naval exercises in the strait spiked shipping insurance and chip-freight, threatening assumptions behind labelled loads.

New audited breakthrough-therapies access programme tabled: fast-track only on logged models with human gates, joint procurement, scarce licensed compute earmarked for audited clinical loads — welcomed by ministers, hospitals questioned source of compute, auditors, pharmacists.
```
